Burns - Pipeline Review, H1 2020
Burns - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2020, provides an overview of the Burns (Dermatology) pipeline landscape.
A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 1, 19, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Burns - Overview
Burns - Therapeutics Development
Burns - Therapeutics Assessment
Burns - Companies Involved in Therapeutics Development
Burns - Drug Profiles
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Burns, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Burns - Pipeline by AlgiPharma AS, H1 2020
Burns - Pipeline by Alliance Pharma Plc, H1 2020
Burns - Pipeline by Anterogen Co Ltd, H1 2020
Burns - Pipeline by Bioharmony Therapeutics Inc, H1 2020
Burns - Pipeline by Biomendics LLC, H1 2020
Burns - Pipeline by CFM Pharma Holding BV, H1 2020
Burns - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
Burns - Pipeline by Combangio Inc, H1 2020
Burns - Pipeline by Destiny Pharma Plc, H1 2020
Burns - Pipeline by Energenesis Biomedical Co Ltd, H1 2020
Burns - Pipeline by FirstString Research Inc, H1 2020
Burns - Pipeline by FortuneRock (China) Ltd, H1 2020
Burns - Pipeline by GNT Pharma Co Ltd, H1 2020
Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H1 2020
Burns - Pipeline by Hypo-Stream Ltd, H1 2020
Burns - Pipeline by Madam Therapeutics BV, H1 2020
Burns - Pipeline by Mallinckrodt Plc, H1 2020
Burns - Pipeline by Marizyme Inc, H1 2020
Burns - Pipeline by MediWound Ltd, H1 2020
Burns - Pipeline by MicroCures Inc, H1 2020
Burns - Pipeline by NeoMatrix Therapeutics Inc, H1 2020
Burns - Pipeline by Novion Technologies Inc, H1 2020
Burns - Pipeline by Phagelux Inc, H1 2020
Burns - Pipeline by Riptide Bioscience Inc, H1 2020
Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2020
Burns - Pipeline by Shulov Innovative Science Ltd, H1 2020
Burns - Pipeline by Stemsynergy Therapeutics Inc, H1 2020
Burns - Pipeline by TGV-Inhalonix Inc, H1 2020
Burns - Pipeline by Theragnostic Technologies Inc, H1 2020
Burns - Pipeline by TreeFrog Therapeutics SAS, H1 2020
Burns - Pipeline by USV Pvt Ltd, H1 2020
Burns - Pipeline by viDA Therapeutics Inc, H1 2020
Burns - Pipeline by Washburn Therapeutics Inc, H1 2020
Burns - Dormant Projects, H1 2020
Burns - Dormant Projects, H1 2020 (Contd..1), H1 2020
Burns - Dormant Projects, H1 2020 (Contd..2), H1 2020
Burns - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Burns, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned
AlgiPharma AS
Alliance Pharma Plc
Anterogen Co Ltd
Bioharmony Therapeutics Inc
Biomendics LLC
CFM Pharma Holding BV
Chrysalis BioTherapeutics Inc
Combangio Inc
Destiny Pharma Plc
Energenesis Biomedical Co Ltd
FirstString Research Inc
FortuneRock (China) Ltd
GNT Pharma Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Hypo-Stream Ltd
Madam Therapeutics BV
Mallinckrodt Plc
Marizyme Inc
MediWound Ltd
MicroCures Inc
NeoMatrix Therapeutics Inc
Novion Technologies Inc
Phagelux Inc
Riptide Bioscience Inc
Se-cure Pharmaceuticals Ltd
Shulov Innovative Science Ltd
Stemsynergy Therapeutics Inc
TGV-Inhalonix Inc
Theragnostic Technologies Inc
TreeFrog Therapeutics SAS
USV Pvt Ltd
viDA Therapeutics Inc
Washburn Therapeutics Inc
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets